Navigation Links
Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
Date:4/28/2009

KVISTGAARD, Denmark, April 28 /PRNewswire-FirstCall/ --

Yesterday Bavarian Nordic Announced its Interim Results for the First Quarter of 2009

- Positive Developments in the Biodefence and Cancer Business Areas

- End of Phase II Meeting Lays Down Pathway for the Licensure of IMVAMUNE(R)

- Preparations for the Delivery of IMVAMUNE(R) to the USA are Progressing According to Plan

- PROSTVAC(TM) Data Have Been Accepted for an Oral Presentation at the ASCO Annual Meeting

In the first quarter of 2009 Bavarian Nordic generated revenue of DKK 17 million and recorded a loss before tax of DKK 83 million. The expectations for the financial result for the full year 2009 are maintained at revenues in the region of DKK 375 million, and a pre-tax loss in the region of DKK 225 million. As of 31 March 2009 the Group's net free liquidity was DKK 627 million.

Highlights from the period

IMVAMUNE(R) - end-of-Phase II meeting held with the FDA

After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. Based on the meeting, Phase III studies are expected to be initiated in 2010.

PROSTVAC(TM) data presented at international cancer symposium

In February 2009, data on PROSTVAC(TM) were presented at the international cancer congress, 2009 Genitourinary Cancers Symposium in Orlando, Florida. The data from three different studies once again confirm the excellent safety and efficacy results previously reported, and they support the further investigation of the vaccine in patients suffering from advanced prostate cancer. The data also indicates that PROSTVAC(TM) may be used in earlier disease settings and thus in a larger patient group.

Important eve
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  UCB, a multinational ... a global leader in designing, transforming, and running ... Award in recognition of their close collaboration in ... UCB,s global business services (GBS) finance organization. ... and clients that work together effectively to embrace ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") ... shares of Resverlogix have approved the resolutions relating ... Limited of 5,600,000 units at a price of ... unit being comprised of one common share and ... of approximately CAD$15 million; and (ii) the amendment ...
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest ... selectivity to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... space to allow easy liquid flow while trapping particulates as small as 0.2 ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... , , ... , Transcriptor Reverse Transcriptase is a new recombinant,reverse transcriptase ... polymerase activity, unwinding,activity, and, importantly, RNase H activity. , ... , Due to the special recombinant structure of Transcriptor,Reverse ...
... , , , ... Protector RNase Inhibitor Is a new type of ... interfere with the performance of enzymes in an assay - even,when high amounts (e.g., ... RNA samples. , Is fully active over a wide pH range of ...
... , , , ... The FastStart Taq DNA Polymerase , ... FastStart Taq DNA Polymerase, a chemically modified version,of Taq DNA Polymerase for hot start PCR, was ... The most robust enzyme preparation,currently available , , ...
Cached Biology Technology:Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 2Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 3Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 4Protector RNase Inhibitor Enhance the Protection of,RNA against Degradation 2Challenge the Performance of Your Hot-Start PCRs,with FastStart Taq DNA Polymerase and,the Novel FastStart High Fidelity PCR System 2
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... release is also available in Chinese on ... stem cell scientists have published new research that improves the ... by Dr Hsiao Chang Chan, from the Chinese University of ... Research into differentiation has led to a variety of breakthroughs ...
... that the drug, ivacaftor (VX-770), significantly improves lung function in ... phase III clinical trial study, "A CFTR Potentiator in Patients ... W. Ramsey, MD of Seattle Children,s Research Institute and the ... England Journal of Medicine . Ivacaftor, also known as ...
... Ill. The conventional wisdom that says the 20th ... more than a myth, according to a forthcoming study ... law., Law professor Paul Heald says overall varietal diversity ... apples in the U.S. actually has increased over the ...
Cached Biology News:Reprogramming stem cells to a more basic form results in more effective transplant, study shows 2Study shows new medication effectively treats underlying cause of cystic fibrosis 2Study: Crop diversity myths persist in media 2Study: Crop diversity myths persist in media 3
... is a fully licensed, high throughput, water bath ... up to 24 microplates. This equates to 9,216 ... ,A robotic arm rapidly transfers a basket of ... ramping times that are considerably faster than those ...
... Ribonuclease is a 27kDa periplasmic enzyme from ... RNA to cyclic nucleotide monophosphate (NMP) intermediates. ... these intermediates to 3-NMPs (1). RNase ONE ... RNases that can cleave a phosophodiester bond ...
... to Dideoxycytidine Dideoxycytidine is a cytidine analog ... inhibiting retroviral activity. Immunogen: Chemical ... Specificity: The specificity of the ddC antiserum ... moles of ddC to moles of ddC analog ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: